PE20131100A1 - Combinacion del compuesto glyt1 con antipsicoticos - Google Patents

Combinacion del compuesto glyt1 con antipsicoticos

Info

Publication number
PE20131100A1
PE20131100A1 PE2013000235A PE2013000235A PE20131100A1 PE 20131100 A1 PE20131100 A1 PE 20131100A1 PE 2013000235 A PE2013000235 A PE 2013000235A PE 2013000235 A PE2013000235 A PE 2013000235A PE 20131100 A1 PE20131100 A1 PE 20131100A1
Authority
PE
Peru
Prior art keywords
alkyl
methanosulfonyl
methanone
piperazin
trifluoro
Prior art date
Application number
PE2013000235A
Other languages
English (en)
Inventor
Daniela Alberati
Jean-Luc Moreau
Joseph G Wettstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131100(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20131100A1 publication Critical patent/PE20131100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE UN FARMACO ANTIPSICOTICO TAL COMO OLANZAPINA, RISPERIDONA, PALIPERIDONA, ARIPIPRAZOL, QUETIAPINA O ZIPRASIDONA Y UN ANTAGONISTA DEL RECEPTOR DE GlyT1 (INHIBIDOR DEL TRANSPORTADOR DE GLICINA) DE FORMULA (I), DONDE Ar ES UN HETEROARILO DE 6 MIEMBROS CON 1 A 3 ATOMOS DE NITROGENO, OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO C1-C6 O HALOALQUILO C1-C6; R1 ES H O ALQUILO C1-C6; R2 ES HALOALQUILO C1-C6; R3, R4 Y R6 SON H, HALOGENO, ALQUILO C1-C6 O ALCOXI C1-C6; R5 ES ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON HALOGENO. SON COMPUESTOS DE FORMULA (I) FAVORITOS: [4-(3-FLUORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANOSULFONIL-2-(2,2,2-TRIFLUORO-1-METIL-ETOXI)-FENIL]-METANONA, rac-[4-(3-CLORO-5-TRIFLUOROMETIL-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANOSULFONIL-2-(2,2,2-TRIFLUORO-1-METIL-ETOXI)-FENIL]-METANONA, rac-[4-(5-BROMO-PIRIDIN-2-IL)-PIPERAZIN-1-IL]-[5-METANOSULFONIL-2-(2,2,2-TRIFLUORO-1-METIL-ETOXI)-FENIL]-METANONA, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA ESQUIZOFRENIA
PE2013000235A 2010-08-09 2011-08-05 Combinacion del compuesto glyt1 con antipsicoticos PE20131100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09

Publications (1)

Publication Number Publication Date
PE20131100A1 true PE20131100A1 (es) 2013-09-23

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000235A PE20131100A1 (es) 2010-08-09 2011-08-05 Combinacion del compuesto glyt1 con antipsicoticos

Country Status (28)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3461834T (pt) 2013-03-13 2021-09-10 Sage Therapeutics Inc Esteroides neuroativos
AR098572A1 (es) * 2013-12-03 2016-06-01 Hoffmann La Roche Composición farmaceutica
KR20160147868A (ko) * 2014-04-30 2016-12-23 위펑 제인 쳉 D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US20170304321A1 (en) * 2014-10-07 2017-10-26 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
CN108135911B (zh) 2015-07-06 2021-06-25 萨奇治疗股份有限公司 氧甾醇及其使用方法
SG10202010553XA (en) 2015-07-06 2020-12-30 Sage Therapeutics Inc Oxysterols and methods of use thereof
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
JP2019532079A (ja) 2016-10-18 2019-11-07 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CA3081226A1 (en) * 2017-11-14 2019-05-23 Sk Biopharmaceuticals Co., Ltd. Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
WO2021142329A1 (en) 2020-01-09 2021-07-15 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009986B1 (ru) 2003-08-11 2008-04-28 Ф. Хоффманн-Ля Рош Аг Пиперазин с or-замещенной фенильной группой и его применение в качестве ингибиторов glyt1
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
ES2520015T3 (es) * 2005-04-08 2014-11-11 Pfizer Products Inc. [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
ES2521596T3 (es) 2014-11-13
MA34457B1 (fr) 2013-08-01
PT2603219E (pt) 2014-11-25
CA2803656A1 (en) 2012-02-16
ECSP13012431A (es) 2013-03-28
KR20130045379A (ko) 2013-05-03
EP2603219A1 (en) 2013-06-19
EA201291477A1 (ru) 2013-06-28
BR112013003068A2 (pt) 2016-06-28
ZA201300434B (en) 2013-09-25
JP2013533297A (ja) 2013-08-22
CN103068388A (zh) 2013-04-24
AR084401A1 (es) 2013-05-15
EP2603219B1 (en) 2014-09-17
KR101455947B1 (ko) 2014-10-28
AU2011288536A1 (en) 2013-01-31
TW201211019A (en) 2012-03-16
NZ604891A (en) 2015-01-30
PL2603219T3 (pl) 2015-03-31
DK2603219T3 (da) 2014-10-13
SI2603219T1 (sl) 2014-12-31
MX2013001166A (es) 2013-03-22
CL2013000378A1 (es) 2013-05-03
CY1115886T1 (el) 2017-01-25
CR20130027A (es) 2013-03-04
US20120035156A1 (en) 2012-02-09
SG187108A1 (en) 2013-02-28
WO2012019970A1 (en) 2012-02-16
AU2011288536B2 (en) 2014-10-09
HRP20141199T1 (hr) 2015-02-13

Similar Documents

Publication Publication Date Title
PE20131100A1 (es) Combinacion del compuesto glyt1 con antipsicoticos
TW200738655A (en) Novel bicyclic sulfonamide derivatives
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
NZ604592A (en) Combinations comprising atypical antipsychotics and taar1 agonists
PE20091353A1 (es) Nuevos compuestos heterociclicos
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
ATE475645T1 (de) Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20091035A1 (es) Derivados de 2-aminopirimidina
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
PE20070586A1 (es) Compuestos de (4-piperidinil)-1,3-dihidro-2h-bencimidazol-2-ona sustituidos como agonistas del receptor muscarinico m1
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20141578A1 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
RS54413B1 (en) [4- (5-AMINOMETHYL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - [7-FLUORO-1- (2-METHOXY-ETHYL) -4TRIFLUOROMETOXY-1H-INDOL-3-IL] METHANONE AS INHIBITOR MASTOCYT TRIPTASES

Legal Events

Date Code Title Description
FC Refusal